Evaluation of Liver Steatosis and Liver Fibrosis in Patients with Type 1 Diabetes Mellitus Using Non-invasive Scores

Read full text Summarise with VIRAT
Authors: Zülal İstemihan, Fatih Bektas, Ali Emre Bardak, Cansu Kiziltas, Gamze Kemec, Ziya Imanov, Ibrahim Volkan Senkal, Kanan Nuriyev, Aynura Rustamzade, Sezen Genc Ulucecen, Hulya Hacisahinogullari, Kubilay Karsidag
+6 more Bilger Cavus, Aslı Cifcibası Ormeci, Filiz Akyuz, Kadir Demir, Fatih Besisik, Sabahattin Kaymakoglu
Cited by: 0
References: 24

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objectives: This study aimed to investigate the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and clinically significant fibrosis (CSF) in patients with type 1 diabetes mellitus (T1DM), as well as the factors affecting them, using non-invasive tests based on blood and imaging methods. Methods: Adult T1DM patients who were followed up in the diabetes mellitus outpatient clinic at a tertiary university hospital and who did not have other causes of liver disease were prospectively investigated. MASLD and CSF were evaluated using non-invasive scores based on biochemical tests and FibroScan®. MASLD was defined as a FibroScan® CAP score ≥275 dB/m, and CSF was defined as F≥8 kPa in the absence of any other chronic liver disease or secondary cause of hepatic steatosis in T1DM patients. Results: The prevalence of MASLD and CSF was 12.9% and 5%, respectively. BMI, fasting blood glucose, and waist and hip circumference were significantly higher in patients with MASLD (p

Fields of Study & Subjects

Liver Disease Diagnosis and Treatment Diabetes Cardiovascular Risks and Lipoproteins Chronic Kidney Disease and Diabetes

Publication details

Journal / source
SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital
Volume
60
Issue
1
Pages
112–119
Publication date
1 January 2026
Language
EN